Company News, Financial News

Johnson & Johnson Q2 Revenues

Neutrogena and Aveeno drive growth in consumer health segment.

Author Image

By: Christine Esposito

Editor-in-Chief

Johnson & Johnson announced results for the second-quarter. Corporate sales were $23.3 billion, up 27.1%.   Consumer health worldwide operational sales of $3.29 billion, excluding the net impact of acquisitions and divestitures, increased 10.0% inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty. Sales growth was driven by skin health/beauty products including Neutrogena, Aveeno, and OGX as well as by J&J’s over-the-counter products ( upper respira...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters